Sec Form 13D Filing - MPM BIOVENTURES V L.P. @ RHYTHM PHARMACEUTICALS INC.

Sec Form 13D Filing - MPM BIOVENTURES V L.P. filing for RHYTHM PHARMACEUTICALS INC. (RYTM) - 2020-06-26

Insider filing report for Changes in Beneficial Ownership

Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

Rhythm Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

76243J 10 5

(CUSIP Number)

Todd Foley

MPM Asset Management

450 Kendall Street

Cambridge, MA 01242

Telephone: (617) 425-9200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

June 24, 2020

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1

CUSIP No. 76243J 10 5


1.		Name of Reporting Persons. MPM BioVentures V, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒ (1)
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

(1)

This schedule is filed by MPM BioVentures V, L.P. (“BV V”), MPM Asset Management Investors BV5 LLC (“AM LLC”), MPM BioVentures V GP LLC (“BV V GP”), MPM BioVentures V LLC (“BV V LLC”) (collectively, the “MPM Entities”) and Ansbert Gadicke, Luke Evnin and Todd Foley (collectively, the “Listed Persons” and together with the MPM Entities, the “Filing Persons”). The Listed Persons are members of BV V LLC and AM LLC. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)	This percentage is calculated based upon 44,091,798 outstanding shares of common stock, par value $0.001 per share, of Rhythm Pharmaceuticals, Inc. (the “Issuer”), as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 4, 2020.

Page 2

CUSIP No. 76243J 10 5


1.		Name of Reporting Persons. MPM Asset Management Investors BV5 LLC
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒ (1)
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

(1)	This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)	This percentage is calculated based upon 44,091,798 outstanding shares of common stock, par value $0.001 per share, of Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 4, 2020.

Page 3

CUSIP No. 76243J 10 5


1.		Name of Reporting Persons. MPM BioVentures V GP LLC
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒ (1)
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

(1)	This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)	Represents shares of Common Stock held by BV V. BV V GP and BV V LLC are the direct and indirect general partners of BV V.

(3)	This percentage is calculated based upon 44,091,798 outstanding shares of common stock, par value $0.001 per share, of Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 4, 2020.

Page 4

CUSIP No. 76243J 10 5


1.		Name of Reporting Persons. MPM BioVentures V LLC
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒ (1)
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

(1)	This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)	Includes shares of Common Stock held by BV V. BV V GP and BV V LLC are the direct and indirect general partners of BV V.

(3)	This percentage is calculated based upon 44,091,798 outstanding shares of common stock, par value $0.001 per share, of Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 4, 2020.

Page 5

CUSIP No. 76243J 10 5


1.		Name of Reporting Persons. Ansbert Gadicke
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒ (1)
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) OO
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization United States

(1)	This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)	Includes 1,838,149 shares of Common Stock held by BV V and 71,409 shares of Common Stock held by AM LLC. BV V GP and BV V LLC are the direct and indirect general partners of BV V. The Reporting Person is a member of BV V LLC.

(3)	This percentage is calculated based upon 44,091,798 outstanding shares of common stock, par value $0.001 per share, of Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 4, 2020.

Page 6

CUSIP No. 76243J 10 5


1.		Name of Reporting Persons. Luke Evnin
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒ (1)
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) OO
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization United States

(1)	This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)	Includes 1,838,149 shares of Common Stock held by BV V and 71,409 shares of Common Stock held by AM LLC. BV V GP and BV V LLC are the direct and indirect general partners of BV V. The Reporting Person is a member of BV V LLC.

(3)	This percentage is calculated based upon 44,091,798 outstanding shares of common stock, par value $0.001 per share, of Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 4, 2020.

Page 7

CUSIP No. 76243J 10 5


1.		Name of Reporting Persons. Todd Foley
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒ (1)
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) OO
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization United States

(1)	This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)	Includes shares issuable upon exercise of stock options within 60 days of June 24, 2020.

(3)	Includes 1,909,558 shares of Common Stock held by BV V and 71,409 shares of Common Stock held by AM LLC. BV V GP and BV V LLC are the direct and indirect general partners of BV V. The Reporting Person is a member of BV V LLC.

(4)	This percentage is calculated based upon 44,091,798 outstanding shares of common stock, par value $0.001 per share, of Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 4, 2020.

Page 8

This Amendment No. 3 to Schedule 13D (“Amendment No. 2”) is being filed as an amendment to the initial statement on Schedule 13D relating to the Common Stock, par value $0.001 per share (the “Common Stock”), of Rhythm Pharmaceuticals, Inc. (the “Issuer”), as filed with the Securities and Exchange Commission (the “SEC”) on October 24, 2017, as amended by Amendment No. 1 filed February 12, 2019 and Amendment No. 2 filed February 5, 2020 (as amended, the “Original Schedule 13D”). This Amendment No. 3 is being filed by the Filing Persons to report the open market sales of shares of the Issuer’s Common Stock by certain Filing Persons.

Items 4, 5 and 7 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment No. 3 but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.

Item 4.

Purpose of Transaction

Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following paragraph at the end of Item 4:

The MPM Entities sold an aggregate of 483,939 shares of the Issuer’s Common Stock in open market transactions pursuant to a 10b5-1 Plan from March 17, 2020 through June 25, 2020 for aggregate proceeds of $10,203,493.34.

Item 5.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer is hereby amended and restated in its entirety as follows:

(a) – (b) The following information with respect to the ownership of the Common Stock of the Issuer by the Filing Persons is provided as of the date of this filing:


Reporting Person	Shares Held Directly		Sole Voting Power		Shared Voting Power			Sole Dispositive Power		Shared Dispositive Power		Beneficial Ownership		Percentage of Class (1)
BV V		1,838,149		1,838,149		0			1,838,149		0		1,838,149		4.2	%
AM LLC		71,409		71,409		0			71,409		0		71,409		0.2	%
BV V GP(2)		0		0		1,838,149			0		1,838,149		1,838,149		4.2	%
BV V LLC(2)		0		0		1,838,149			0		1,838,149		1,838,149		4.2	%
Ansbert Gadicke(3)		0		0		1,909,558			0		1,909,558		1,909,558		4.3	%
Luke Evnin(3)		0		0		1,909,558	&#x A0;		0		1,909,558		1,909,558		4.3	%
Todd Foley(3)(4)		25,000		0		1,909,558			25,000		1,909,558		1,934,558		4.4	%

(1)	This percentage is calculated based upon 44,091,798 outstanding shares of common stock, par value $0.001 per share, of Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 4, 2020.

(2)	Includes securities held by BV V. BV V GP and BV V LLC are the direct and indirect general partners of BV V.

(3)	Includes securities held by BV V and AM LLC. The Reporting Person is a member of BV V LLC.

(4)	Includes shares issuable upon exercise of stock options within 60 days of June 24, 2020.

Page 9

(c) The Reporting Persons sold the following shares of Common Stock in the open market in the sixty days preceding the date of this filing:


Date	Price Range		Average Price		BV V Sold		AM LLC Sold
4/28/2020	$	20.00 - $20.225	$	20.07		15,234		592
4/29/2020	$	20.00 - $20.30	$	20.12		19,634		763
5/6/2020	$	20.00	$	20.00		1,565		61
5/7/2020	$	20.00 - $20.01	$	20.01		193		7
5/8/2020	$	20.00 - $20.21	$	20.05		6,385		248
5/11/2020	$	20.00 - $20.55	$	20.34		21,326		829
5/12/2020	$	20.00 - $20.48	$	20.23		23,432		910
5/13/2020	$	20.00 - $20.135	$	20.04		1,768		69
5/18/2020	$	20.00 - $20.04	$	20.00		20,551		798
5/19/2020	$	20.00 - $20.02	$	20.00		2,535		98
5/20/2020	$	20.00 - $20.05	$	20.01		10,133		394
5/21/2020	$	20.00 - $20.50	$	20.25		24,637		957
5/22/2020	$	20.00 - $20.29	$	20.13		25,900		1,006
5/26/2020	$	20.12 - $20.74	$	20.47		42,760		1,661
5/27/2020	$	20.00 - $20.24	$	20.13		9,768		380
5/28/2020	$	20.00 - $20.35	$	20.19		18,436		716
6/1/2020	$	20.00 - $20.14	$	20.08		10,141		394
6/2/2020	$	20.00 - $20.53	$	20.23		14,995		583
6/3/2020	$	20.00 - $20.88	$	20.27		17,563		682
6/5/2020	$	20.00	$	20.00		1,825		71
6/24/2020	$	25.00 - $25.545	$	25.34		93,746		3,642
6/25/2020	$	25.00 - $25.71	$	25.41		17,276		671

The information provided and incorporated by reference in Item 3 and Item 6 is hereby incorporated by reference in this Item 5.

(d) Not applicable.

(e) The Reporting Persons ceased to be the beneficial owners of more than five percent of the class of securities on May 20, 2020.

Item 7.

Material to Be Filed as Exhibits

A.	Agreement regarding filing of joint Schedule 13D.

Page 10

Signatures

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: June 26, 2020


MPM BIOVENTURES V GP LLC

By:		MPM BioVentures V LLC,
		its Managing Member

By:		/s/ Todd Foley
Name:		Todd Foley
Title:		Member

MPM BIOVENTURES V LLC

By:		/s/ Todd Foley
Name:		Todd Foley
Title:		Member

MPM BIOVENTURES V, L.P.

By:		MPM BioVentures V GP LLC, its General Partner
By:		MPM BioVentures V LLC, its Managing Member

By:		/s/ Todd Foley
Name:		Todd Foley
Title:		Member

MPM ASSET MANAGEMENT INVESTORS BV5 LLC

By:		/s/ Howard Rubin
Name:		Howard Rubin
Title:		Authorized Signatory

By:		/s/ Todd Foley
Name:		Todd Foley

By:		/s/ Luke Evnin
Name:		Luke Evnin

By:		/s/ Ansbert Gadicke
Name:		Ansbert Gadicke

Page 11

Schedule I

General Partners/Members

Ansbert Gadicke

c/o MPM Asset Management

450 Kendall Street

Cambridge, MA 02142

Principal Occupation: Member of the managing member of the general partner of MPM BioVentures V, L.P. Citizenship: USA

Luke Evnin

c/o MPM Asset Management

450 Kendall Street

Cambridge, MA 02142

Principal Occupation: Member of the managing member of the general partner of MPM BioVentures V, L.P.

Citizenship: USA

Todd Foley

c/o MPM Asset Management

450 Kendall Street

Cambridge, MA 02142

Principal Occupation: Member of the managing member of the general partner of MPM BioVentures V, L.P.

Citizenship: USA

Page 12

Exhibit Index

A.	Agreement regarding filing of joint Schedule 13D.

Page 13

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With:

Sole Voting Power

1,838,149

Shared Voting Power

0

Sole Dispositive Power

1,838,149

Shared Dispositive Power

0